Drug Profile
Denosumab biosimilar - Jiangsu T-Mab Biopharma
Alternative Names: 9MW-0311; 9MW-0321; MAILISHU; MW-031; MW-032; TK-006Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Jiangsu T-mab BioPharma
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postmenopausal osteoporosis
- Phase III Bone metastases
- No development reported Bone cancer
Most Recent Events
- 21 Feb 2024 Adverse events, pharmacokinetics and efficacy data from a phase III trial in Bone metastases released by Mabwell Therapeutics
- 22 Jan 2024 The Russian Ministry of Health approves regulatory application for phase III clinical trial in Postmenopausal osteoporosisin Russia
- 22 Jan 2024 Mabwell Therapeutics plans a phase III trial for Postmenopausal osteoporosis in Russia (Injection)